Orion Oyj (OTCMKTS:ORINY) Sees Significant Drop in Short Interest

Orion Oyj (OTCMKTS:ORINY) was the target of a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 300 shares, a decrease of 50.0% from the February 28th total of 600 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average trading volume of 1,400 shares, the days-to-cover ratio is presently 0.2 days.

Orion Oyj Price Performance

Orion Oyj stock traded up $0.68 during mid-day trading on Friday, hitting $29.35. 680 shares of the company traded hands, compared to its average volume of 3,220. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.41 and a current ratio of 2.42. Orion Oyj has a one year low of $17.50 and a one year high of $30.57. The stock has a market cap of $8.28 billion, a price-to-earnings ratio of 23.29 and a beta of 0.25. The stock has a fifty day moving average price of $27.98 and a 200-day moving average price of $25.68.

Orion Oyj (OTCMKTS:ORINY) last posted its quarterly earnings data on Tuesday, February 25th. The company reported $0.28 earnings per share (EPS) for the quarter. The company had revenue of $463.41 million during the quarter. Orion Oyj had a net margin of 23.01% and a return on equity of 39.49%. On average, equities analysts predict that Orion Oyj will post 1.18 earnings per share for the current fiscal year.

Orion Oyj Increases Dividend

The company also recently disclosed a dividend, which will be paid on Tuesday, April 29th. Stockholders of record on Monday, April 7th will be issued a $0.4478 dividend. This is a boost from Orion Oyj’s previous dividend of $0.24. The ex-dividend date is Monday, April 7th. Orion Oyj’s dividend payout ratio is presently 24.00%.

Wall Street Analysts Forecast Growth

Separately, Nordea Equity Research downgraded Orion Oyj to a “hold” rating in a research report on Tuesday, February 4th.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.